Search

The article presents contradictory opinions on whether topoisomerase II alpha is a valid biomarker for taxane sensitivity.

The discusses research which showed that positron emission tomography/computed tomography (PET/CT) scanning was not able to replace lymphadenectomy for locoregional lymph node staging in patients with large primary breast tumors, but may be valuable in detecting distant metastases. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." The study found that primary tumors were identified in all patients using PET/CT and magnetic resonance imaging (MRI).

The article discusses research on the effectiveness of supplementing an anthracycline-based therapy with taxane in increasing the survival rate of high-risk early breast cancer patients. It references a study published in a 2008 issue of the "Journal of Clinical Oncology." Researchers have examined hazard ratios and confidence intervals for disease-free survival and overall survival from trials. The study revealed that taxane administration could have an absolute five-year risk reduction of 3% overall survival and 5% for disease-free survival.